Advertisement
Advertisement
U.S. Markets open in 8 hrs 28 mins
Advertisement
Advertisement
Advertisement
Advertisement

Rezolute, Inc. (RZLT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.0900+0.1100 (+3.69%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.9800
Open3.0500
Bid3.0000 x 2200
Ask4.0500 x 800
Day's Range2.9400 - 3.1300
52 Week Range2.2600 - 17.3900
Volume35,875
Avg. Volume220,001
Market Cap47.71M
Beta (5Y Monthly)3.62
PE Ratio (TTM)N/A
EPS (TTM)-3.0140
Earnings DateFeb 08, 2022 - Feb 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.80
  • GlobeNewswire

    Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress

    Announced a $130 million registered direct offering and concurrent private placement Positive topline results from Phase 2b RIZE study of RZ358 exceeded expectations and demonstrated highly significant reduction in hypoglycemia events, ~75% at anticipated therapeutic doses Positive data from Phase 1b multiple-ascending dose study of RZ402 enable Phase 2 proof-of-concept study initiation later this year REDWOOD CITY, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinic

  • GlobeNewswire

    Rezolute to Host Corporate Update Call on May 4, 2022

    Company to Host Analyst and Investor Conference Call on Wednesday, May 4 at 4:30 p.m. ETREDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that management will be hosting a corporate update call. The call will highlight recent pipeline advancements and continued

  • GlobeNewswire

    Rezolute, Inc. Announces Closing of Registered Direct Offering

    REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced the closing of its previously announced underwritten registered direct offering of an aggregate of 18,026,315 shares of its common stock at an offering price of $3.80 per share, and, to certain investors in lieu

Advertisement
Advertisement